Antibody engineering & therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA
Matthias Pauthner(Scripps Research Institute), Joost P.M. Melis(Genmab (Netherlands)), Joost M. Bakker(Broadcom (Israel)), Fridtjof Lund‐Johansen(Oslo University Hospital), Janice M. Reichert(Framingham State University), Jenny Yeung(The London College), Paul J. Carter(Seagen (United States)), Thierry Wurch(Servier (France)), Andrew Bradbury(Q2 Solutions (United States)), Chris Ullman(TiGenix (Spain))
Cited by 7
Related Papers
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance
|Cell|2019|469
Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen
|Science|2015|449
Antibody-Drug Conjugates for Cancer Therapy
|The Cancer Journal|2008|431